Zentrela Inc., the leading Canadian neurotechnology company, is proud to announce that Health Canada has authorized its novel EEG-based research model for Level 3 non-therapeutic cannabis effect studies, unlocking the ability to provide Canadian LPs with objective and regulatory-compliant product effect evidence.
While a Level 1 NTRC license allows for sensory testing, it is sometimes also used to informally collect reported cannabis effect information. However, this latter type of non-scientific data is not reliable nor compliant with Health Canada’s NTRC regulatory framework, therefore its value is limited. For example, it cannot be used publicly for budtender education programs, unlike the sensory data.
The Level 3 NTRC was created to enable Canadian cannabis companies to generate product effect evidence using scientific research instruments like EEG devices through interventional studies based on the full consumption of pre-commercialized products.
Zentrela’s unique EEG-driven research model for objectively quantifying the psychoactive and mood effects of cannabis products is the result of 7+ years of R&D to master the ability to combine proprietary portable EEG technology with Machine Learning to characterize cannabis effects accurately and affordably. Since 2021, Zentrela has been continuously refining its EEG-based research solution, generating more algorithms and standardizing its master research protocol to make it the most objective, fast-to-conduct, and replicable solution in the market.
“This is a game-changing event for the Canadian cannabis industry and Zentrela,” said company founder and CEO Israel Gasperin. “Before our offering, there didn’t exist a standardized, objective, and quantifiable way of characterizing cannabis effects. Health Canada’s authorization of our EEG-driven research methodology is making the activation of Level 3 NTRC studies very straightforward and affordable. Instead of investing in regulatory consulting fees to start an L3 NTRC application process from scratch, now LPs can work with us right away to unlock the business benefits of generating product effect evidence objectively and in compliance with the Cannabis Act and its regulations.”
For further information, contact Roy Agostino at (416) 659-0678.
About Zentrela, Inc.
Zentrela Inc., a trailblazer in the field of cannabis research, harnesses advanced EEG technology to objectively study the effects of cannabis on the human brain. Our commitment to scientific rigour, credibility, and innovation makes us a leader in providing actionable insights for the cannabis industry. Visit Zentrela’s website to learn more.
Content sponsored by: Zentrela Inc.